Literature DB >> 22154554

Unverricht-Lundborg disease: homozygosity for a new splicing mutation in the cystatin B gene.

Eugénia Pinto1, Joel Freitas, Ana Joana Duarte, Isaura Ribeiro, Diogo Ribeiro, J Lopes Lima, João Chaves, Olga Amaral.   

Abstract

Unverricht-Lundborg disease is the most common form of progressive myoclonic epilepsy (PME). It is due to cystatin B gene (CSTB) mutations. Several mutations in CSTB gene have been published, but few in homozygosity. We describe a patient with a new splicing alteration. Mutation Gln22Gln leads to abnormal splicing and partial inclusion of intronic sequence. This is one of the few cases of homozygosity for a non-classic mutation and adds to mutational heterogeneity of CSTB. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154554     DOI: 10.1016/j.eplepsyres.2011.11.004

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  Progressive volume loss and white matter degeneration in cstb-deficient mice: a diffusion tensor and longitudinal volumetry MRI study.

Authors:  Otto Manninen; Teemu Laitinen; Kimmo K Lehtimäki; Saara Tegelberg; Anna-Elina Lehesjoki; Olli Gröhn; Outi Kopra
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

2.  Characterization of a rare Unverricht-Lundborg disease mutation.

Authors:  Ana Joana Duarte; Diogo Ribeiro; João Chaves; Olga Amaral
Journal:  Mol Genet Metab Rep       Date:  2015-08-05

3.  Correction of a Splicing Mutation Affecting an Unverricht-Lundborg Disease Patient by Antisense Therapy.

Authors:  Liliana Matos; Ana Joana Duarte; Diogo Ribeiro; João Chaves; Olga Amaral; Sandra Alves
Journal:  Genes (Basel)       Date:  2018-09-11       Impact factor: 4.096

4.  In Silico Analysis of Missense Mutations as a First Step in Functional Studies: Examples from Two Sphingolipidoses.

Authors:  Ana Joana Duarte; Diogo Ribeiro; Luciana Moreira; Olga Amaral
Journal:  Int J Mol Sci       Date:  2018-10-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.